Related Experiment Video
Updated: Jun 29, 2025
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
Published on: March 8, 2024
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to
Jon Salmanton-García1,2,3, Francesco Marchesi4, Francesca Farina5
1University of Cologne, Faculty of Medicine, and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
Insights
COVID-19 posed significant risks for hematological malignancy patients, but outcomes improved over time. Vaccination and later infection dates were linked to better survival, though hospitalization remained a concern.
Area of Science:
- Hematology
- Infectious Diseases
- Oncology
Background:
- The COVID-19 pandemic disproportionately affected individuals with hematological malignancies due to compromised immunity.
- Standard interventions for COVID-19 may offer reduced efficacy in this vulnerable patient group.
Purpose of the Study:
- To analyze COVID-19 outcomes in patients with hematological malignancies using data from the EPICOVIDEHA registry.
- To identify trends in critical infections, mortality, and survival factors over the first three years of the pandemic.
Main Methods:
- Data were collected from January 2020 to December 2022 via the EPICOVIDEHA registry (NCT04733729).
- The study included 8767 COVID-19 cases from 152 centers across 41 countries.
- Analysis focused on mortality rates, critical infections, and factors influencing survival.
Main Results:
- Overall mortality decreased from 29% to 4% between 2020 and 2022.
- Vaccination (1-2 or 3+ doses) and contracting COVID-19 in 2022 were associated with improved survival.
- Hospitalization, particularly ICU admission, remained linked to higher mortality.
Conclusions:
- Despite improvements, hematological malignancy patients remain at high risk for severe COVID-19.
- Vaccination and timely 2022 exposure are crucial for better survival outcomes.
- Continued monitoring and targeted interventions are vital for this population.
Background:
The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced.
Methods:
The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data from hematological malignancy patients since the pandemic's start worldwide. It spans various global locations, allowing comprehensive analysis over the first three years (2020-2022).
Findings:
The EPICOVIDEHA registry collected data from January 2020 to December 2022, involving 8767 COVID-19 cases in hematological malignancy patients from 152 centers across 41 countries, with 42% being female. Over this period, there was a significant reduction in critical infections and an overall decrease in mortality from 29% to 4%. However, hospitalization, particularly in the ICU, remained associated with higher mortality rates. Factors contributing to increased mortality included age, multiple comorbidities, active malignancy at COVID-19 onset, pulmonary symptoms, and hospitalization. On the positive side, vaccination with one to two doses or three or more doses, as well as encountering COVID-19 in 2022, were associated with improved survival.
Interpretation:
Patients with hematological malignancies still face elevated risks, despite reductions in critical infections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The study underscores the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable population, emphasizing the critical role of timely diagnosis and prompt treatment in preventing severe COVID-19 cases.
Funding:
Not applicable.
More Related Videos
08:01Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
08:02In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
01:24Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency...
01:01Regulation of Hematopoietic Stem Cells